Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Eur J Endocrinol. 2022 Jul 25;187(3):429–437. doi: 10.1530/EJE-22-0285

Table 4.

Presentation and outcomes of patients based on maximum cyst size and growth rate. Data are presented as n (%) or as median (range).

Variable Maximum cyst size
Cyst growth rate
< 50 mm ≥ 50 mm P-value <5mm/year >5mm/year P-value

n 38 54 44 15
Age at diagnosis, years 52 (14–81) 37 (20–76) 0.0003 48 (14–83) 36 (19–68) 0.2844
Women 23 (61%) 29 (54%) 0.5309 26 (59%) 7 (47%) 0.5485
Symptoms of mass effect 0 (0%) 9 (17%) 0.0093 3 (7%) 2 (13%) 0.5933
Initial cyst size, mm 35 (5–49) 61 (20–88) <0.001 48 (11–104) 46 (17–100) 0.5833
Unenhanced CT attenuation, HU 20 (0–83) 19 (9–70) 0.7643 20 (5–83) 20 (9–50) 0.8733
Cyst growth rate#, mm per year +0.6 (−2.5 to 6) +3.6 (−9 to 27) 0.0887
Change in cyst size#,$, mm +3 (−38 to 30) +12.5 (−60 to 111) 0.0495 +2.3 (−60 to 73) +39 (6 to 111) <0.0001
Surgical intervention, n (%) 12 (32%) 34 (63%) 0.0056 10 (23%) 13 (87%) <0.0001

Abbreviations used: CT = computed tomography; HU = Hounsfield units

P value < 0.05 is significant

#

Available for 59 patients with more than 6 months of imaging follow-up

$

Difference between cyst size on last and the first imaging studies